Доступ предоставлен для: Guest
Портал Begell Электронная Бибилиотека e-Книги Журналы Справочники и Сборники статей Коллекции
Critical Reviews™ in Oncogenesis
SJR: 0.946 SNIP: 0.503 CiteScore™: 2

ISSN Печать: 0893-9675
ISSN Онлайн: 2162-6448

Critical Reviews™ in Oncogenesis

DOI: 10.1615/CritRevOncog.v17.i1.30
pages 17-30

Therapeutic Targeting of BCR-ABL: Prognostic Markers of Response and Resistance Mechanism in Chronic Myeloid Leukaemia

David T. Yeung
Haematology Department, SA Pathology (RAH Site), Centre for Cancer Biology, and University of Adelaide, Adelaide, Australia.
Timothy P. Hughes
Haematology Department, SA Pathology (RAH Site), Centre for Cancer Biology, and University of Adelaide, Adelaide, Australia

Краткое описание

Chronic myeloid leukemia (CML) is caused by the formation of the BCR-ABL fusion protein as a result of the t(9;22) chromosomal translocation. The elucidation of its molecular pathogenesis led to the identification of a therapeutic target and the subsequent synthesis and introduction of a small-molecule inhibitor for this target, imatinib. Because CML is the first disease successfully treated by targeted kinase inhibition, it served as a paradigm for discovery of disease mechanism and drug development in other diseases in which constitutive kinase expression plays a central role in pathogenesis. Despite the spectacular success of imatinib, not all CML patients derive great benefit from it. This review will cover some of the currently known prognostic markers of disease response and potential resistance mechanisms.

Ключевые слова: imatinib, nilotinib, dasatinib, OCT-1, MMR, CCyR, kinase domain mutation

Articles with similar content:

IL-7 and Its Beneficial Role in Sepsis-Induced T Lymphocyte Dysfunction
Critical Reviews™ in Immunology, Vol.38, 2018, issue 6
Fabienne Venet, Charles de Roquetaillade, Guillaume Monneret, Morgane Gossez
Roles Each of Snail, Yin Yang 1, and RKIP in the Regulation of Tumor Cells Chemo- Immuno-Resistance to Apoptosis
Forum on Immunopathological Diseases and Therapeutics, Vol.4, 2013, issue 1
Sara Huerta-Yepez, Mario I. Vega, Ali R. Jazirehi, Stavroula Baritaki, Benjamin Bonavida
Attractin: Cautionary Tales for Therapeutic Intervention in Molecules with Pleiotropic Functionality
Journal of Environmental Pathology, Toxicology and Oncology, Vol.23, 2004, issue 1
Jonathan S. Duke-Cohan, Abdallah Azouz, Jeong H. Kim
Recent Advances in Cancer Stem Cell Targeted Therapy
Critical Reviews™ in Oncogenesis, Vol.24, 2019, issue 1
Muge Ocal, Hakan Akbulut, Samira Abdi Abgarmi, Merve Besler, Cansu Babahan
Yin Yang 1 (YY1): Regulation of Survivin and Its Role In Invasion and Metastasis
Critical Reviews™ in Oncogenesis, Vol.22, 2017, issue 1-2
Nicholas R. Galloway, Kathryn F. Ball, Nathan R. Wall, TessaRae Stiff